BRIEF published on 07/06/2026 at 19:19, 1 month 21 days ago ABIONYX's Half-Yearly Review of the Liquidity Contract Liquidity Transactions TP ICAP Actions ABIONYX Pharma
BRIEF published on 07/06/2026 at 19:19, 1 month 21 days ago Bilan semestriel du contrat de liquidité d'ABIONYX Transactions TP ICAP Actions Liquidité ABIONYX Pharma
PRESS RELEASE published on 07/06/2026 at 19:14, 1 month 21 days ago Informations privilégiées / Autres communiqués Bilan semestriel du contrat de liquidité portant sur les actions de la société ABIONYX Pharma, confié à la Société TP ICAP (Europe) SA, avec détails des transactions et soldes en espèces Contrat Bilan Semestriel Transactions Liquidité ABIONYX Pharma
BRIEF published on 06/30/2026 at 19:13, 1 month 27 days ago ABIONYX Pharma en pleine expansion après son Assemblée Générale ABIONYX Pharma Sepsis CER-001 Assemblée Générale 2026 Plateforme ApoA-I
BRIEF published on 06/30/2026 at 19:13, 1 month 27 days ago ABIONYX Pharma Secures Funding to Advance Sepsis Treatment ABIONYX Pharma CER-001 Financial Funding Sepsis Treatment ApoA-I Platform
BRIEF published on 06/30/2026 at 19:13, 1 month 27 days ago ABIONYX Pharma obtient des fonds pour faire progresser le traitement de la septicémie ABIONYX Pharma CER-001 Traitement De La Septicémie Plateforme ApoA-I Financement Financier
BRIEF published on 06/30/2026 at 19:13, 1 month 27 days ago ABIONYX Pharma is expanding rapidly following its General Meeting ABIONYX Pharma Sepsis CER-001 General Assembly 2026 ApoA-I Platform
PRESS RELEASE published on 06/30/2026 at 19:08, 1 month 27 days ago Inside Information / Other news releases ABIONYX Pharma scales up operations after securing resources, focusing on value creation in inflammation and sepsis treatment. Updates on pivotal clinical trial, financial visibility, and scientific platform development Financial Resources Clinical Trial ABIONYX Pharma Sepsis Inflammation Treatment
PRESS RELEASE published on 06/30/2026 at 19:08, 1 month 27 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma change d'échelle suite à la sécurisation des moyens de son ambition et ouvre un nouveau cycle de création de valeur dans les inflammations sévères et le sepsis ABIONYX Pharma Sepsis Création De Valeur Innovantes Inflammations Sévères
BRIEF published on 06/18/2026 at 07:35, 2 months 10 days ago ABIONYX Pharma finalise avec succès un financement de 33 millions d'euros. Augmentation De Capital ABIONYX Pharma Fenja Capital Financement Par Obligations Recherche Sur La Septicémie
Published on 08/28/2026 at 14:00, 2 hours 20 minutes ago Lobe Sciences Expands Leadership Team with New CFO Appointment
Published on 08/28/2026 at 13:00, 3 hours 20 minutes ago Abasca Files NI 43-101 Technical Report, Commences Summer Exploration Program at Loki and Elects to File Semi-annual Interim Financial Statements and Related MD&A
Published on 08/28/2026 at 08:05, 8 hours 15 minutes ago Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Published on 08/28/2026 at 08:05, 8 hours 15 minutes ago Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Published on 08/28/2026 at 08:00, 8 hours 20 minutes ago Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Published on 08/28/2026 at 15:55, 25 minutes ago Form 8.3 - The Vanguard Group, Inc.: DNO Iraq AS (a wholly owned subsidiary of DNO ASA)
Published on 08/28/2026 at 15:54, 25 minutes ago Viromed Medical AG receives ÜTS registration for ViroCAP® in Turkey and can fulfill existing orders
Published on 08/26/2026 at 18:02, 1 day 22 hours ago Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:02, 1 day 22 hours ago Altareit : Communiqué de presse d’Altarea relatif au dossier Primonial
Published on 08/26/2026 at 18:00, 1 day 22 hours ago Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
